With completion of second successful pivotal trial, company targeting Q4 2016 for NDA filing for SYM-1219 for the treatment of BV Newark, NJ, May 26, 2016 – Symbiomix today announced positive results from the second pivotal trial of lead product candidate SYM-1219 (secnidazole) for the treatment of bacterial vaginosis (BV). SYM-1219 is a potent, next-generation Read more…
Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing
Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food
Targeting mid-2016 for NDA filing for SYM-1219 for the treatment of bacterial vaginosis Newark, NJ, September 21, 2015 – Symbiomix Therapeutics presented data this past Friday, September 18, at the 2015 joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy (ICC) in San Diego, CA describing the pharmacokinetics of lead product SYM-1219 Read more…
Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation
Targeting mid-2016 for NDA filing for SYM-1219 for the treatment of Bacterial Vaginosis
Newark, NJ, August 27, 2015 – Symbiomix today announced the completion of patient enrollment in a Phase 3 clinical study, the second pivotal trial of SYM-1219, which is a single-dose, oral product candidate for the treatment of bacterial vaginosis (BV). Read More….